Farxiga vs Metformin Cost and Access Head-to-Head

What These Two Drugs Actually Do

Metformin suppresses hepatic glucose production and improves peripheral insulin sensitivity through activation of AMP-activated protein kinase (AMPK). Dapagliflozin blocks the sodium-glucose cotransporter-2 (SGLT2) in the proximal tubule of the kidney, forcing roughly 70 grams of glucose per day into the urine. The two mechanisms are entirely different, which is why the drugs are routinely combined rather than simply swapped.

Mechanism: Metformin

Metformin's primary action is in the liver, where it reduces gluconeogenesis. It also modestly improves skeletal-muscle glucose uptake and may alter the gut microbiome in ways that affect glycemia. Average HbA1c reduction is 1.0% to 1.5% from baseline, comparable to most other oral agents [1].

Mechanism: Dapagliflozin

Dapagliflozin's glucosuric action is insulin-independent, meaning it works even when beta-cell function is severely impaired. Beyond glycemia, the osmotic and natriuretic effects of glucosuria reduce preload, afterload, and intraglomerular pressure. These hemodynamic changes are the likely driver of dapagliflozin's heart-failure and kidney-protection signals, which appear within weeks of starting therapy [2].

Cost Comparison: Metformin vs Farxiga

The price gap between these two drugs is among the widest in outpatient diabetes care. Metformin is one of the least expensive medications in the world. Farxiga is still patent-protected in the United States and carries a brand-tier price that prices out many uninsured patients entirely.

Metformin Pricing

Generic metformin immediate-release 500 mg, 1000 mg, and 850 mg tablets are available at virtually every US pharmacy. GoodRx pricing for a 60-tablet supply of metformin 500 mg runs approximately $4 to $8 depending on the pharmacy. Extended-release metformin (metformin ER, also branded as Glucophage XR) costs slightly more, but generics remain under $20 per month for most doses. The FDA approved metformin for Type 2 diabetes in 1994 [3], and the patent has been expired long enough that generic competition has pushed prices to commodity levels.

Farxiga Pricing

As of 2025, Farxiga (dapagliflozin 10 mg, 30 tablets) lists at approximately $560 to $610 per month at major US retail pharmacies. No FDA-approved generic exists in the United States as of the article's last review date. AstraZeneca's patient-assistance program, AZ&Me, may reduce or eliminate out-of-pocket costs for qualifying patients earning below 400% of the federal poverty level [4]. Commercially insured patients with Tier 3 or Tier 4 formulary placement may still face $50 to $150 monthly copays after the manufacturer's savings card.

Insurance Coverage Realities

Medicare Part D plans are prohibited from using manufacturer copay cards, so Medicare beneficiaries without Low Income Subsidy (LIS) face full tier cost-sharing for Farxiga. The Inflation Reduction Act insulin cap does not cover SGLT2 inhibitors. Medicaid coverage varies by state; some states place dapagliflozin on preferred formulary for members with documented heart failure or CKD, aligning with guideline indications [5].

Efficacy: What the Trials Actually Showed

No head-to-head randomized controlled trial has directly compared dapagliflozin against metformin as monotherapy in a glycemia-primary design with an adequate sample size. Published comparisons come from network meta-analyses and indirect data. The two landmark trials below were designed for different patient populations and different outcomes, so direct numeric comparison requires caution.

UKPDS 34: The Metformin Evidence Base

The UK Prospective Diabetes Study 34 (UKPDS 34), published in The Lancet in 1998, enrolled 1,704 overweight patients with newly diagnosed Type 2 diabetes and randomized 342 to intensive metformin therapy [6]. Over a median follow-up of 10.7 years, the metformin group showed a 32% reduction in any diabetes-related endpoint compared with conventional (diet-only) therapy (P<0.0023) and a 36% reduction in all-cause mortality (P<0.011). HbA1c reduction was approximately 0.6 percentage points greater with metformin than with conventional therapy at three years. UKPDS 34 remains the foundational cardiovascular-outcomes evidence for metformin and the reason it secured its first-line position in global guidelines [6].

DAPA-HF: The Dapagliflozin Evidence Base

DAPA-HF, published in the New England Journal of Medicine in 2019, enrolled 4,744 patients with heart failure with reduced ejection fraction (HFrEF, EF <40%) and randomized them to dapagliflozin 10 mg once daily or placebo on top of optimized guideline-directed medical therapy [7]. The primary composite outcome of worsening heart failure or cardiovascular death was reduced by 26% with dapagliflozin (HR 0.74; 95% CI 0.65 to 0.85; P<0.001). 45% of participants in DAPA-HF did not have Type 2 diabetes at baseline, establishing that the cardiac benefit is independent of glucose lowering [7]. Metformin was not tested in this population.

DECLARE-TIMI 58: Broader Cardiovascular Picture

The DECLARE-TIMI 58 trial (N=17,160), published in the New England Journal of Medicine in 2019, tested dapagliflozin 10 mg vs placebo in patients with Type 2 diabetes who either had established ASCVD or multiple risk factors [8]. Dapagliflozin did not significantly reduce the primary MACE endpoint in the overall population but did reduce the composite of CV death or hospitalization for heart failure by 17% (HR 0.83; 95% CI 0.73 to 0.95) and reduced the rate of renal events by 24% [8].

DAPA-CKD: Kidney Protection

DAPA-CKD (N=4,304), also published in the New England Journal of Medicine in 2020, tested dapagliflozin 10 mg in patients with CKD (eGFR 25 to 75 mL/min/1.73m²) regardless of diabetes status [9]. The primary composite of sustained decline in eGFR of 50% or more, end-stage kidney disease, or death from kidney or cardiovascular causes was reduced by 39% (HR 0.61; 95% CI 0.51 to 0.73; P<0.001) [9]. Metformin is generally contraindicated or dose-restricted in the CKD populations studied in DAPA-CKD.

Guideline Positioning: Where Each Drug Sits

The 2024 American Diabetes Association Standards of Care place metformin as an appropriate first-line pharmacological option for most adults with Type 2 diabetes, particularly when cost and tolerability are prioritized [10]. The ADA specifies: "Metformin remains an effective, low-cost therapy and may be continued when an SGLT2 inhibitor or GLP-1 receptor agonist is added for patients who tolerate it" [10].

For patients with established ASCVD, heart failure, or CKD, the ADA recommends an SGLT2 inhibitor with proven benefit (dapagliflozin among them) independent of HbA1c or the need for additional glucose lowering [10]. The European Society of Cardiology 2023 guidelines similarly recommend SGLT2 inhibitors for all patients with Type 2 diabetes and heart failure, regardless of ejection fraction [11].

When Metformin Takes Priority

• Type 2 diabetes without established cardiovascular disease or CKD
• Normal or near-normal eGFR (eGFR >45 mL/min/1.73m²)
• Patients who are uninsured or underinsured with limited formulary access
• Pediatric Type 2 diabetes (metformin is FDA-approved for ages 10 and up) [3]

When Dapagliflozin Takes Priority

• Documented HFrEF or HFpEF requiring additional heart-failure risk reduction
• CKD with eGFR 25 to 75 mL/min/1.73m² and urinary albumin-to-creatinine ratio >200 mg/g
• Type 2 diabetes with established ASCVD or high 10-year cardiovascular risk
• Patients already at HbA1c target who need organ protection rather than additional glucose lowering

Safety Profiles: A Side-by-Side View

Neither drug is free of adverse effects, but the types of risk differ considerably.

Metformin Safety

Gastrointestinal side effects (nausea, diarrhea, abdominal cramping) affect 20% to 30% of patients starting metformin; switching to the extended-release formulation reduces GI complaints in most cases [12]. Lactic acidosis is rare, estimated at 3 to 10 cases per 100,000 patient-years, but risk rises with significant renal impairment, acute illness, or contrast media exposure [12]. Metformin does not cause hypoglycemia when used as monotherapy. Long-term use can deplete vitamin B12; the ADA recommends periodic B12 monitoring in patients on chronic metformin [10].

Dapagliflozin Safety

Genital mycotic infections (vulvovaginal candidiasis and balanitis) affect roughly 6% to 8% of dapagliflozin users, compared with 2% to 3% on placebo [13]. Urinary tract infection rates are modestly elevated. Diabetic ketoacidosis (DKA) is rare but possible, particularly in patients who are fasting, volume-depleted, or who have undiagnosed Type 1 diabetes; dapagliflozin's FDA label carries a DKA warning [4]. Fournier's gangrene (necrotizing fasciitis of the perineum) has been reported with SGLT2 inhibitors class-wide, with the FDA issuing a safety communication in 2018 [14]. Volume depletion and modest blood-pressure reduction are common at initiation and require attention in elderly patients or those on diuretics [13].

Renal Dosing Boundaries

Metformin should be held when eGFR falls below 30 mL/min/1.73m² and used with caution between 30 and 45 mL/min/1.73m² [10]. Farxiga's glucose-lowering effect diminishes as eGFR drops (less filtered glucose, less glucosuria), but the drug retains its kidney-protective indication down to eGFR <25 mL/min/1.73m² in the CKD setting [4].

Head-to-Head on HbA1c Reduction

A 2021 network meta-analysis published in Diabetes Care (N=232 trials, approximately 100,000 participants) found that SGLT2 inhibitors as a class produced mean HbA1c reductions of approximately 0.8% as monotherapy, compared with 1.0% to 1.2% for metformin in drug-naive patients [15]. Metformin retains a modest numeric edge in glucose lowering for patients starting from higher baseline HbA1c levels, particularly above 9%. Dapagliflozin's glucose-lowering advantage is greatest in patients with preserved renal function and high baseline HbA1c, but organ-protection benefits appear regardless of glycemic effect [7].

Weight and Blood Pressure Effects

Both drugs produce modest weight loss in most patients, which distinguishes them from sulfonylureas and insulin. Metformin typically produces 1 to 3 kg of weight loss over 12 to 24 weeks, partly by reducing appetite [16]. Dapagliflozin produces 2 to 3 kg of weight loss attributable to caloric loss via glucosuria plus modest osmotic diuresis [8]. Neither drug approaches the 10% to 15% body-weight reductions seen with GLP-1 receptor agonists at maximum doses.

On blood pressure, dapagliflozin reduces systolic BP by 3 to 5 mmHg through natriuresis, an effect that can be therapeutically useful in hypertensive diabetic patients but requires monitoring in those prone to hypotension [8]. Metformin has no clinically meaningful blood-pressure effect [6].

Drug Interactions and Monitoring Requirements

Metformin Interactions

Carbonic anhydrase inhibitors (topiramate, zonisamide) may increase lactic acidosis risk. Cimetidine and other renal tubular secretion inhibitors can raise metformin plasma levels. Iodinated contrast media require temporary metformin cessation in patients with eGFR <60 mL/min/1.73m² per FDA guidance [3].

Dapagliflozin Interactions

Dapagliflozin has few pharmacokinetic drug interactions because it is metabolized primarily by UGT1A9 rather than CYP450 enzymes. Concurrent use of loop diuretics raises the risk of volume depletion; dose adjustment or monitoring may be needed [4]. Co-administration with insulin or insulin secretagogues increases hypoglycemia risk modestly.

Monitoring Schedules

Patients on metformin should have eGFR checked at baseline and at least annually, with B12 levels checked every 2 to 3 years [10]. Patients on dapagliflozin need baseline eGFR, urinalysis, and periodic reassessment; the FDA label recommends against starting Farxiga for glucose lowering when eGFR <45 mL/min/1.73m², though the CKD and HF indications have different eGFR thresholds [4].

Access Pathways and Patient-Assistance Programs

Metformin Access

Metformin is on every major pharmacy's $4 generic list, on Walmart's $4 or $10 prescription program, and is covered by virtually all Medicaid formularies without prior authorization. Access barriers are minimal for US patients. Internationally, metformin is included on the WHO Model List of Essential Medicines, making it available in most low- and middle-income countries at negligible cost [17].

Farxiga Access

AstraZeneca offers AZ&Me, a prescription savings program for uninsured or underinsured patients. The manufacturer's copay card (Farxiga Savings Card) caps monthly out-of-pocket costs at $10 for eligible commercially insured patients, but this card cannot be used by Medicare or Medicaid beneficiaries. Prior authorization is required by most commercial plans before Farxiga will be covered, and payers frequently require documented cardiovascular disease, CKD, or HF diagnosis to approve it for the organ-protection indication [5]. Some payers require metformin failure or intolerance before approving SGLT2 inhibitors for glucose-lowering-only indications.

Decision Framework: Choosing Between the Two

Use this clinical decision structure to select or combine therapy:

| Patient Profile | Preferred Starting Agent | |---|---| | New-onset T2D, no CVD/CKD/HF, cost-sensitive | Metformin | | T2D plus HFrEF (EF <40%) | Add dapagliflozin regardless of HbA1c | | T2D plus CKD (eGFR 25 to 75, ACR >200) | Add dapagliflozin per DAPA-CKD data | | T2D plus established ASCVD | SGLT2 inhibitor or GLP-1 RA; metformin as add-on | | eGFR <30 mL/min/1.73m² | Dapagliflozin (CKD indication); metformin contraindicated | | Pediatric T2D (age 10 to 17) | Metformin (FDA-approved); dapagliflozin not approved <18 | | Uninsured, no assistance program eligibility | Metformin |

Combination Use: Both Drugs Together

Guidelines do not position these drugs as alternatives requiring a choice in most patients with established cardiovascular or kidney disease. The ADA 2024 Standards of Care explicitly support using metformin alongside an SGLT2 inhibitor when both are tolerated, because the mechanisms are complementary and additive on HbA1c [10]. A 2019 study in Diabetes, Obesity and Metabolism (N=900) found that dual initiation of dapagliflozin plus metformin produced significantly greater HbA1c reduction at 24 weeks compared with either drug alone, with no increase in serious adverse events [18]. Clinicians should not interpret this comparison as a forced binary choice.

Pregnancy and Special Populations

Metformin crosses the placenta. Some guidelines allow continued use in gestational diabetes or preconception Type 2 diabetes management, but insulin remains the reference standard for glycemic control during pregnancy [19]. Dapagliflozin is FDA Pregnancy Category warning: animal studies show fetal renal toxicity; the drug should be discontinued at confirmation of pregnancy and is not recommended during the second or third trimester [4].

For older adults (age >75), both drugs require renal monitoring. Dapagliflozin's diuretic effect increases fall risk from volume depletion and orthostatic hypotension; the ADA recommends individualized therapy goals in older adults with frailty [10].